Abstract
Get full access to this article
View all access options for this article.
References
1.CRISPR Therapeutics and Vertex Pharmaceuticals. CRISPR Therapeutics and Vertex Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia . 2023 . Available from: https://crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-and-vertex-complete-submission-of-rolling-biologics-license-applications-blas-to-the-us-fda-for-exa-cel-for-the-treatment-of-sickle-cell-disease-and-transfusion-dependent-beta-thalassemia [Last accessed: April 12, 2023].
2.Sartorius Stedim Biotech. Sartorius Stedim Biotech to Acquire Polyplus . 2023 . Available from: https://www.polyplus-transfection.com/news/sartorius-acquire-polyplus/ [Last accessed: April 12, 2023].
3.Moderna and Generation Bio. Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines . 2023 . Available from: https://investors.modernatx.com/news/news-details/2023/Moderna-and-Generation-Bio-Announce-Strategic-Collaboration-to-Develop-Non-Viral-Genetic-Medicines/default.aspx [Last accessed: April 12, 2023].
4.Ginkgo Bioworks. Ginkgo Bioworks Strengthens End-to-End R&D Capabilities in Gene Therapy through Acquisition of StrideBio's AAV Capsid Discovery and Engineering Platform Assets . 2023 . Available from: https://investors.ginkgobioworks.com/news/news-details/2023/Ginkgo-Bioworks-Strengthens-End-to-End-RD-Capabilities-in-Gene-Therapy-through-Acquisition-of-StrideBios-AAV-Capsid-Discovery-and-Engineering-Platform-Assets/default.aspx [Last accessed: April 12, 2023].
5.VintaBio. VintaBio Unveils $64M to Back Viral Vector Trailblazers Behind the First Approved Cell and Gene Therapies . 2023 . Available from: https://www.prnewswire.com/news-releases/vintabio-unveils-64m-to-back-viral-vector-trailblazers-behind-the-first-approved-cell-and-gene-therapies-301793833.html [Last accessed: April 12, 2023].
6.Center for Breakthrough Medicines. Center for Breakthrough Medicines Now Provides a Clinically Tested Adherent Manufacturing Platform for AAV Production . 2023 . Available from: https://breakthroughmedicines.com/all/center-for-breakthrough-medicines-now-provides-a-clinically-tested-adherent-manufacturing-platform-for-aav-production/ [Last accessed: April 12, 2023].